LAUR vs UTI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: LAUR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LAUR and UTI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LAUR and UTI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Laureate Education (Nasdaq: LAUR) runs a network of private universities and higher-education institutions concentrated in two markets, Mexico (brands including UVM and UNITEC) and Peru (UPC, UPN, and the CIBERTEC technical institute). After years of selling off a sprawling global portfolio, the company reshaped itself into a streamlined operator focused on these two countries, where a growing middle class and limited public-university capacity drive demand for affordable degree and technical programs. Total enrollment sits near 500,000 students, and revenue is earned largely in Mexican pesos and Peruvian soles, which makes reported results sensitive to foreign-exchange swings.

Full LAUR guide

Universal Technical Institute, Inc. (NYSE: UTI) runs postsecondary vocational schools across two reportable segments. The legacy UTI segment trains students in automotive, diesel, motorcycle, marine, welding, CNC and related skilled trades, while the Concorde Career Colleges segment (acquired in 2022) offers allied health, dental, nursing, patient-care and diagnostic programs. The company generates revenue primarily from student tuition, much of it funded through federal Title IV financial aid, and it has been growing student starts and average full-time enrollment at both segments.

Full UTI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LAUR drivers: Enrollment and campus expansion; Margin expansion and cash generation.
• UTI drivers: Skilled-trades demand tailwind; Concorde and healthcare diversification.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Because nearly all revenue is earned in Mexican pesos and Peruvian soles, a weakening of those currencies against the US dollar can compress reported results even when local operations grow. For UTI, uTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LAUR if you believe its drivers more; UTI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LAUR and UTI guides.

LAUR. Laureate trades at roughly a mid-teens earnings multiple and around 10x EV/EBITDA, valuations that sit below many US-listed education peers, reflecting its emerging-market currency exposure. The company reaffirmed 2026 revenue guidance near $1.9 billion and lifted its adjusted EPS outlook after buybacks. Q1 2026 revenue grew about 15% year over year to roughly $273 million, though the first quarter carries a seasonal net loss.

UTI. Fiscal 2025 revenue grew about 14% and net income rose roughly 50% to about $63 million. Fiscal 2026 guidance calls for revenue near $905 to $915 million but net income of only about $40 to $45 million, reflecting roughly $40 million of growth-investment spending. The premium P/E reflects investor expectations that campus expansion will lift future earnings.

Headline figures (approximate, JULY 2026): LAUR shows revenue (ttm) ~$1.75B, adjusted ebitda (fy2025) ~$510M, market cap ~$5.1B, p/e (trailing) ~17x; UTI shows revenue (fy2025) ~$835.6M, revenue guidance (fy2026) ~$905-915M, net income (fy2025) ~$63M, adjusted ebitda (fy2025) ~$126.5M.

LAUR and UTI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LAUR and UTI exposure against your real portfolio. It is not an investment adviser.